Bay, Benjamin
Fuh, Marceline M.
Rohde, Julia
Worthmann, Anna
Goßling, Alina
Arnold, Natalie
Koester, Lukas
Lorenz, Thiess
Blaum, Christopher
Kirchhof, Paulus
Blankenberg, Stefan
Seiffert, Moritz
Brunner, Fabian J.
Waldeyer, Christoph
Heeren, Joerg
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 9 April 2024
Accepted: 13 June 2024
First Online: 26 June 2024
Declarations
:
: An ethics vote was obtained from the local ethics committee (PV4303, Hamburg, Germany), and written and informed consent was acquired from all participants.
: Not applicable.
: NA reports grant and personal fees from Novartis outside of the submitted work. PK receives research support for basic, translational, and clinical research projects from European Union, British Heart Foundation, Leducq Foundation, Medical Research Council (UK), and German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past, but not in the last three years. PK is listed as inventor on two issued patents held by University of Hamburg (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). SB reports research funding/grants from Abbott Diagnostics, Siemens, AMGEN, Astra Zeneca, Novartis and Daiichi Sankyo; Honoraria for lectures/chairs from Abbott, AMGEN, Bayer, Boehringer Ingelheim, Bristol Meyer Squib, Daiichi Sankyo, GlaxoSmithKline, LumiraDx, Novartis, Roche Diagnostics and Thermo Fisher; and is a member of the advisory board/consultant for Thermo Fisher. MS reports personal fees from Abiomed, AMGEN, AstraZeneca, Bristol-Myers Squibb, Daichii Sankyo, Inari Medical, Pfizer, Shockwave Medical, and Siemens Healthineers, personal fees and non-financial support from Abbott Vascular, Edwards Lifesciences, and Medtronic, and grants, personal fees and non-financial support from Boston Scientific and Philips, all outside the submitted work. FB reports grants from Daiichi Sankyo, Pfizer, and Sanofi, non-financial support from Abbott, ASAHI INTECC, and Inari Medical, personal fees from Amgen and Novartis outside of the submitted work. CW reports lecture and consulting fees from AMGEN, Novartis, Daiichi Sankyo, Sanofi and AstraZeneca, all outside of the submitted work. JH received honoraria for lectures from AMGEN, Pfizer, Daichii Sankyo and Eli Lilly, all outside of the submitted work. All other authors have nothing to declare.
: Part of this work has previously been presented at the 91st Congress of the European Atherosclerosis Society, 21st -23rd May 2023, Mannheim, Germany.